Alnylam Seeking Lumasiran Approvals Soon, But Has Two Rivals On Its Heels
Executive Summary
Phase III results support early 2020 filings for what could be the RNAi specialist’s third commercial product, but two competing drugs for primary hyperoxaluria from Dicerna and OxThera aren’t far behind.
You may also be interested in...
Finance Watch: Investors Launch New SPACs After Initial Deals
EcoR1 and Casdin/Corvex took their second and third special purpose acquisition corporations public. Also, Ionis sold notes to buy back older notes and fund operations as it cut 70% of Akcea’s staff. In venture capital, ValenzaBio raised $70m and RA boosted Metagenomi’s series A to $75m.
Alnylam Turns To Value-Based Pricing Again For Oxlumo
As with its first two approved RNAi therapies, Alnylam will negotiate value-based agreements with payers, but for Oxlumo, approved in pediatric patients, it will offer a patient need adjustment.
Alnylam Shows Efficacy, Safety With Lumasiran In Vulnerable Pediatric Patients
The top-line data in the ultra-rare disease are also the first to demonstrate safety and efficacy of an RNAi therapy in patients six years and younger.